First interim analysis of OTILIA, a large German non-interventional study evaluating bevacizumab-containing therapy in patients with ovarian cancer. 27. Juli 2015 Mustea, A., Mahner, S., Oskay-Oezcelik, G., Wimberger, P., Jungberg, S., Reichert, D., Forstbauer, H., Keller, M., Richter, R., Frank, M., Klawitter, S., Kiewitz, C., Müller, M., Sehouli, J., 2015. ESMO Annual Meeting (Vienna) Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany. Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Meinerz, Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Meinerz, W., 2015. Annual… Weiterlesen Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR. Fietz, T., Kurbacher, C.M., Trarbach, T., Salat, C., Rezai, M., Lorenz, A., Niemeier, B., 2016. Oncol Res Treat 39 (suppl3)(P952), 293. doi:10.1159/000449050… Weiterlesen